University of California conducts first-in-human Study of the drug in Pancreatic Cancer

University of California, Davis is recruiting patients for first-in-human Study of the Theranostic Pair [68Ga]Ga DOTA-5G and [177Lu]Lu DOTA-ABM-5G in Pancreatic Cancer.

This is a Phase I, first-in-human study to evaluate the safety and efficacy of the [68Ga]Ga DOTA-5G and [177Lu]Lu DOTA-ABM-5G theranostic pair in patients with locally advanced or metastatic pancreatic adenocarcinoma (PDAC).

The researchers plan that January 2021 will be the study start date. The indicative completion of the clinical trial will be expected in December 2024.

The study will take place at the University of California Davis, Sacramento, California, United States.

There are a number of conditions that do not allow participation, such as:

  • Participant on any chemical anticoagulant including antiplatelet agents (excluding ASA).
  • Participants with Class 3 or 4 NYHA Congestive Heart Failure.
  • Clinically significant bleeding within two weeks prior to trial entry (e.g. gastrointestinal bleeding, intracranial bleeding).
  • Pregnant or lactating women.
  • Major surgery, defined as any surgical procedure that involves general anesthesia and a significant incision (i.e. larger than what is required for placement of a central venous access, percutaneous feeding tube, or biopsy) within 28 days prior to study day 1 or anticipated surgery within the subsequent 6 weeks.

and others.

The University of California, Davis (UC Davis, UCD, or Davis) is a public research university and land-grant university located near Davis, California. It is one of the ten campuses of the University of California system, and has the third-largest enrollment in the system after UCLA and UC Berkeley.

The page dedicated to this clinical trial can be found here: https://ichgcp.net/clinical-trials-registry/NCT04665947

Clinical Research News

Upcoming Clinical Trials

3